

Q-Med AB: Invitation to conference call regarding interim report January-September, 2009

Time: Friday, October 23, 2009 at 10.30 a.m. CET.

To join the conference: Swedish dial in number: +46 8 5052 0114
UK dial in number: +44 207 1620 177

Q-Med participants: Bengt Ågerup, CEO
Alexander Kotsinas, CFO
Karin Falck, Director Corporate Communications

Q-Med AB's Q3 report will be released 08.00 on October 23, 2009.

The slide presentation will be available at www.q-med.com, and Investors/Presentations.

A recorded version of the presentation will be available for seven working days on tel: Sweden +46 8 505 203 33 or UK +44 20 7031 4064, access code: 84 83 70.

Financial information from Q-Med during 2010

12 February	Year-end Report 2009
23 April	Interim Report January - March 2010
28 April	Annual General Meeting
22 July	Interim Report January – June 2010
22 October	Interim Report January – September 2010

Queries should be addressed to:

Karin Falck, Director Corporate Communications
Tel: +46 70 974 90 15

Q-Med AB is a medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, **NASHA™**, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: **Restylane®** for filling lines and folds, contouring and creating volume in the face, **Macrolane™** for body contouring, **Durolane™** for the treatment of osteoarthritis of the hip and knee joints, **Deflux®** for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and **Solesta™** for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has about 650 coworkers, with approximately 400 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the NASDAQ OMX Nordic.
